Join Steve Hunt at Medidata NEXT New York for a roundtable discussion on real world lessons from early adopters of Medidata Designer. Steve will share what effective adoption looks like in practice, where ICON teams are ...

The oncology R&D landscape is rapidly evolving, driven by multi‑modality therapeutics, precision‑designed studies, and the growing measurable impact of AI on discovery and development. These shifts are reshaping how spon...

Last week, our teams across ICON came together to recognise Rare Disease Day and raise awareness for the millions of people and families living with rare conditions. Colleagues took part in activities including creating...

Vaccine guidance for patients with rare autoimmune diseases can be challenging, given the low prevalence of some of these conditions and limited understanding of the impacts of vaccines in these patients. Discover how va...

Rare autoimmune diseases can leave patients particularly vulnerable to infection, but they often require unique considerations for vaccination. Learn what makes these cases so unique, and what to take into account when b...

China’s life‑sciences sector continues to advance rapidly, creating new opportunities for more efficient and globally competitive clinical development. In ICON’s latest blog, Yao Zhong outlines the key factors enabling i...

Join ICON at #OCT Southeast on 10 March at 9:30am EST as Shelley McLendon, Senior Vice President, Program Management, shares a CRO perspective on the global biotech sector. She will discuss the landscape shaping biotec...

Non-invasive testing could transform the management of metabolic liver disease and help shape the future of MASH clinical development. This article in SelectScience® Science explores the evolving NIT landscape, emerging...

On 15 April at 12:00 pm, join ICON’s Alan Baldridge at the GLP‑1‑Based Therapeutics Summit for his session, “Is there anything GLP‑1s can’t do? Unlocking the next generation of metabolic treatments.” He will offer a fo...

Recent findings highlight the continued relevance and reliability of the Oswestry Disability Index instrument for evaluating disability in patients with Degenerative Disc Disease. Study participants demonstrated strong...

Neuroscience programmes demand reliable feasibility, broad patient access, and operational consistency across regions. At ADPD 2026, stop by booth \#29 to learn how ICON combines informatics driven feasibility, extensi...

On 17-21 March at #ADPD2026, visit us at booth #29 to speak with our experts to learn how ICON is working to improve drug development and advance treatments for Alzheimer’s and Parkinson's disease and other movement diso...